JRSM >
Volume 99, Number 3 >
Pp. 132-140
1 Medical Research Institute of New Zealand, Wellington
2 Wellington School of Medicine & Health Sciences, Wellington, New
Zealand
Correspondence to: Professor Richard Beasley E-mail: richard.beasley{at}mrinz.ac.nz
Objectives: To examine whether the increased risk of cardiovascular events with rofecoxib represents a class effect of cyclooxygenase-2 (COX-2) specific inhibitors.
Design: Systematic review and meta-analysis of randomized double-blind clinical trials of celecoxib of at least 6 weeks' duration and presented data on serious cardiovascular thromboembolic events. Data sources included six bibliographic databases, the relevant files of the United States Food and Drug Administration, and pharmaceutical company websites.
Main outcome measures: Pooled fixed effects estimates of the odds ratios for risk of cardiovascular events with celecoxib compared with comparator treatment were calculated using the inverse variance weight method. The main outcome measure was myocardial infarction.
Results: Four placebo-controlled trials with 4422 patients were included in the primary meta-analysis comparing celecoxib with placebo. The odds ratio of myocardial infarction with celecoxib compared to placebo was 2.26 (95%confidence interval 1.0 to 5.1). For composite cardiovascular events [odd ratio 1.38 (95% CI 0.91 to 2.10)], cardiovascular deaths [OR 1.06 (95% CI 0.38 to 2.95)] and stroke [OR 1.0(95% CI 0.51 to 1.84)] there was no significant increase in risk with celecoxib. The secondary meta-analysis which included a total of six studies (with placebo, diclofenac, ibuprofen, and paracetamol as comparators) of 12 780 patients, showed similar findings with a significant increased risk with celecoxib for myocardial infarction [OR 1.88 (95% CI 1.15 to 3.08)] but not other outcome measures.
Conclusion: The available data indicate an increased risk of myocardial infarction with celecoxib therapy, consistent with a class effect for COX-2 specific inhibitors.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Related articles in JRSM:
This article has been cited by other articles:
|
|
 |
|
  M W van der Linden, S van der Bij, P Welsing, E J Kuipers, and R M C Herings The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs Ann Rheum Dis, May 1, 2009; 68(5): 668 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kleinert, C. Lange, A. Steup, P. Black, J. Goldberg, and P. Desjardins Single Dose Analgesic Efficacy of Tapentadol in Postsurgical Dental Pain: The Results of a Randomized, Double-Blind, Placebo-Controlled Study Anesth. Analg., December 1, 2008; 107(6): 2048 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, and G. D. Kitas Hypertension in rheumatoid arthritis Rheumatology, September 1, 2008; 47(9): 1286 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. I. Sidiropoulos, G. Hatemi, I.-H. Song, J. Avouac, E. Collantes, V. Hamuryudan, M. Herold, T. K. Kvien, H. Mielants, J. M. Mendoza, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists Rheumatology, March 1, 2008; 47(3): 355 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P A Scott, G H Kingsley, C M Smith, E H Choy, and D L Scott Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials Ann Rheum Dis, October 1, 2007; 66(10): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gamerdinger, A. B. Clement, and C. Behl Cholesterol-Like Effects of Selective Cyclooxygenase Inhibitors and Fibrates on Cellular Membranes and Amyloid-beta Production Mol. Pharmacol., July 1, 2007; 72(1): 141 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Brune and D. E. Furst Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology, June 1, 2007; 46(6): 911 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. E. Zarraga and E. R. Schwarz Coxibs and Heart Disease: What We Have Learned and What Else We Need to Know J. Am. Coll. Cardiol., January 2, 2007; 49(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Andersohn, S. Suissa, E. Garbe, S. Solomon, J. Wittes, N. Arber, M. Bertagnolli, E. Hawk, B. Levin, the APC and PreSAP Trial Investigators, et al. Risks and Benefits of Celecoxib to Prevent Colorectal Adenomas N. Engl. J. Med., November 30, 2006; 355(22): 2371 - 2373. [Full Text] [PDF]
|
|
|
|
 |
|
 P. McGettigan and D. Henry Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2 JAMA, October 4, 2006; 296(13): 1633 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, E. L. Ding, and Y. Song Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials JAMA, October 4, 2006; 296(13): 1619 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Dalby, D. N. Frank, A. L. St. Amand, A. M. Bendele, and N. R. Pace Culture-independent analysis of indomethacin-induced alterations in the rat gastrointestinal microbiota. Appl. Envir. Microbiol., October 1, 2006; 72(10): 6707 - 6715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chaiamnuay, J. J. Allison, and J. R. Curtis Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1837 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Cheung and S. Lowry Celecoxib J R Soc Med, July 1, 2006; 99(7): 336 - 336. [Full Text] [PDF]
|
|
|
|
|
|
P. Dieppe Complicity theory: an explanation for the ;coxib problem'? J R Soc Med, June 1, 2006; 99(6): 273 - 274. [Full Text] [PDF]
|
|
|
|
|
|
M. Weatherall, S. Aldington, B. Caldwell, and R. Beasley Inconsistencies in cardiovascular data from COX-2 inhibitor trials--is it a class effect? J R Soc Med, June 1, 2006; 99(6): 275 - 276. [Full Text] [PDF]
|
|
|
|
 |
|
 Celecoxib and Cardiovascular Risk Journal Watch Cardiology, March 30, 2006; 2006(330): 3 - 3. [Full Text]
|
|
